Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deffered Revenue (2018 - 2021)

Summit Therapeutics (SMMT) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $365000.0 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $365000.0, compared with a TTM value of $365000.0 through Jun 2021, changed N/A, and an annual FY2020 reading of $569000.0, up 15.42% over the prior year.
  • Non-Current Deffered Revenue was $365000.0 for Q2 2021 at Summit Therapeutics, down from $383000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $715000.0 in Q3 2020 and bottomed at $365000.0 in Q2 2021.
  • Average Non-Current Deffered Revenue over 3 years is $505000.0, with a median of $493000.0 recorded in 2019.
  • Peak annual rise in Non-Current Deffered Revenue hit 15.42% in 2020, while the deepest fall reached 15.42% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $493000.0 in 2019, then grew by 15.42% to $569000.0 in 2020, then tumbled by 35.85% to $365000.0 in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for SMMT at $365000.0 in Q2 2021, $383000.0 in Q1 2021, and $569000.0 in Q4 2020.